Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD

Pomerantz LLP filed a class action lawsuit against Aardvark Therapeutics (NASDAQ: AARD) and certain officers/directors, alleging claims under the Securities Act of 1933 and Securities Exchange Act of 1934. The suit covers purchases of Aardvark stock tied to its Feb 13, 2025 IPO and other Aardvark securities acquired between Feb 13, 2025 and May 14, 2026. While no financial damages are specified, the litigation risk is a near-term overhang for the shares.

Analysis

This is primarily a cost-of-capital event, not a product-event. For a small-cap therapeutic issuer, the market will care less about eventual damages than about the higher probability of a punitive financing path: defense spend, D&O scrutiny, and a wider discount on any follow-on raise or strategic transaction. That matters because even a routine securities case can force a pre-revenue biotech to trade like a "future dilution" story rather than a pipeline story.

The second-order losers are the recent IPO cohort and any similarly situated biotech names that still need external capital. If this becomes part of a broader pattern, D&O pricing can tighten and underwriters will demand more conservative disclosures, which compresses multiples across the group over the next 6-18 months. For AARD specifically, the stock can stay under pressure well beyond the first headline because litigation creates an earnings-free overhang that is hard for generalists to underwrite.

Contrarian view: these cases are often noise unless they expose a very specific disclosure gap or a real financing/cash-runway issue. If the complaint is boilerplate and the company has enough runway to avoid an immediate raise, the initial selloff may overshoot and fade after the first legal procedures. The thesis is falsified by early dismissal, clear insurance coverage, or a company-specific catalyst that re-centers the stock on fundamentals rather than litigation.

Key Decisions for Investors

• Short AARD on any relief rally over the next 1-5 sessions; target 15-25% downside over 1-3 months, with a tight cover trigger if the company discloses a strong cash runway or the case is dismissed early.
• If options are liquid, buy 3-6 month AARD put spreads rather than outright puts to reduce theta; structure for a limited-loss, event-driven downside move tied to motion-to-dismiss/financing headlines.
• Pair trade: short AARD vs long XBI for 1-3 months to isolate litigation idiosyncrasy from biotech beta; this works best if broader biotech risk appetite remains stable.
• Set an alert for any secondary offering, PIPE, or D&O insurance commentary over the next 1-3 months; those are the highest-probability catalysts for a second leg lower.